SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Director/PDMR Shareholding

12 Feb 2026 15:26

RNS Number : 8282S
Victrex PLC
12 February 2026
 

12 February 2026

Victrex plc

Grant of Nil-Cost Options

On 12 February 2026 (the "Grant Date") the Company granted awards in the form of nil-cost options over a total of 318,449 ordinary shares in Victrex to Dr. James Routh, Chief Executive Officer, comprising:

 

(a) three standalone awards over the number of shares specified in the table below, which reflect three long-term incentive awards forfeited by Dr Routh as a result of him ceasing to be an employee of his previous employer, AB Dynamics plc, in order to join Victrex, as agreed as part of his recruitment package (the "Buyout Awards")

 

 

Number of Victrex shares

Normal Vesting Date*

Part 1 of the 2023 LTIP Buy-Out Award

25,530

4 December 2025

2024 LTIP Buy-Out Award

54,538

8 February 2027

2025 LTIP Buy-Out Award

66,380

29 November 2027

 

\* The Awards will vest on the later of their Normal Vesting Date and the date on which the extent of achievement against the applicable performance conditions is determined and approved by the Victrex Remuneration Committee.

 

(b) two awards under the Victrex 2019 Long Term Incentive Plan (the "LTIP") over 21,501 Shares ("Part 2 of the 2023 LTIP Buy-Out Award") and 150,500 Shares (the "2026 LTIP Award").

 

Buyout award terms

 

The buy-out arrangements were structured in accordance with the principles set out in the Company's approved Directors' Remuneration Policy, in particular that they are limited to a reasonable estimate of value of remuneration lost when leaving the former employer and reflect the delivery mechanism, time horizons and performance requirements attached to that remuneration. The structure of the awards mirrors what was forfeited on leaving AB Dynamics, and the conversion into Victrex shares on joining provides alignment with Victrex shareholders. The Buyout Awards (including Part 2 of the 2023 LTIP Buy-Out Award) are, therefore, subject to the same performance conditions (where applicable) and post-vesting holding periods as the forfeited AB Dynamics LTIP awards. Further details will be contained within the 2026 Directors' Remuneration Report.

 

The Buyout Awards (including Part 2 of the 2023 LTIP Buy-Out Award) will become exercisable on the same dates as the awards they replace (provided the Company's remuneration committee can assess the extent to which the performance conditions are met) and any shares acquired are subject to the same holding periods.

 

The number of ordinary shares over which the Buyout Awards were granted was based on the mid-market closing share price of Victrex and AB Dynamics plc on 31 December 2025, being the latest dealing date prior to Dr. Routh commencing employment with Victrex on 1 January 2026.

The exercise of the Buyout Awards will not be satisfied with an issue of shares or a transfer of treasury shares.

2026 LTIP Award

The 2026 LTIP Award has been granted with a value representing 175% of Dr Routh's base salary as at the Grant Date.

The 2026 LTIP Award will vest based on the achievement of EPS, TSR, ROIC and sustainability targets over a 3-year performance period. The detailed performance conditions will be provided in the 2026 Directors' Remuneration Report. The 2026 LTIP Award is subject to a holding period ending on the fifth anniversary of the date of grant.

The number of shares over which the 2026 LTIP Award was granted was calculated based on a share price of £6.9767, being the mid-market price quoted over a three-day average immediately preceding the Grant Date.

Notes:

As a result of these transactions, Dr. James Routh holds options over 318,449 ordinary shares in the Company.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

Enquiries:

Andrew Hanson, Director of Investor Relations, Corporate Communications & ESG +44 (0) 7809 595831

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy & Industrial, Electronics and Medical. Every day, millions of people rely on products or applications which contain our sustainable materials, from smartphones, aircraft and cars to energy operations and medical devices. With over 40 years' experience, we are moving beyond the polymer into semi-finished and finished products which shape future performance for our customers and our markets, enable environmental and societal benefit for our customers and drive value for our shareholders. Find out more at www.victrexplc.com

Registered Office: Victrex Technology Centre, Hillhouse International, Thornton Cleveleys, Lancashire, FY5 4QD

Registered Number: 2793780, England and Wales

 

Buyout Awards

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

James Routh

2.

Reason for the notification

(a)

Position/status

Chief Executive Officer

(b)

Initial notification/ Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

Victrex plc

(b)

LEI

213800UYNPHAUNHPXL67

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial Instrument

Nil-cost options over ordinary shares of 1p each

Identification code of the Financial Instrument

GB0009292243

(b)

Nature of the transaction

Grant of nil-cost options to acquire ordinary shares in the Company in compensation for awards forfeited on leaving former employer

(c)

Price(s) and volume(s)

Price(s)

Volume

Nil

25,530

Nil

54,538

Nil

66,380

(d)

Aggregated information:

- Aggregated volume

 

- Price

 

N/A

Nil

(e)

Date of the transaction

12 February 2026

(f)

Place of the transaction

Outside a trading venue

 

 

2026 LTIP Award

1.

Details of the person discharging managerial responsibilities/person closely associated

(a)

Name

James Routh

2.

Reason for the notification

(a)

Position/status

Chief Executive Officer

(b)

Initial notification/ Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

(a)

Name

Victrex plc

(b)

LEI

213800UYNPHAUNHPXL67

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

(a)

Description of the Financial Instrument

Nil-cost options over ordinary shares of 1p each

Identification code of the Financial Instrument

GB0009292243

(b)

Nature of the transaction

Grant of two LTIP awards (in the form of nil-cost options to acquire ordinary shares in the Company)

 

(c)

Price(s) and volume(s)

Price(s)

Volume

Nil

21,501

Nil

150,500

(d)

Aggregated information:

- Aggregated volume

 

- Price

 

N/A

Nil

(e)

Date of the transaction

12 February 2026

(f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGMZKZKGVZM
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.